Endoscopic management of intestinal strictures in Crohn's disease: Commentary
β Scribed by Asher Kornbluth
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 45 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
β¦ Synopsis
B efore moving on to specific carping and criticisms of the topic at hand, it should be noted that the points of view of Dr. Koltun and Dr. Van Assche et al, thoroughly outline the state of the art, such as it is, of the pros and cons of endoscopic stricture dilation in Crohn's disease (CD). 1,2 The salient, albeit limited and uncontrolled, series are cited and reviewed, and there is agreement on the most important practical consideration, that is, the type of patient and type of stricture most likely to benefit from endoscopic dilation-a symptomatic, relatively short, straight, endoscopically accessible, benign, preferably fibrotic (rather than inflammatory and ulcerated) stricture, in a patient who is not acutely ill. These features are most commonly found in a patient with a stricture at a postsurgical ileocolic anastamosis.
π SIMILAR VOLUMES
## Background: So far, infliximab (ifx) therapy for the treatment of crohn's disease (cd) has generally been guided by clinical symptoms. data on treatment response as ascertained by endoscopy in ifx therapy are scarce. the aims of this study were to measure the endoscopic response rate during ifx
Background: Stricture formation occurs in %30% of patients with Crohn's disease (CD) and is a significant cause of morbidity. Strictures are characterized by intestinal smooth muscle cell hyperplasia, smooth muscle cell hypertrophy, and fibrosis due to excess net extracellular matrix production, inc